Allarity Therapeutics ALLR Income Statement (2020-2026)

NASDAQ ALLR
$1.43 +0.00 (+0.00%)
As of: Aug 20, 2026 · 3:59 PM EDT
Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
6.0010.008.0010.0011.0012.0011.0032.00621.000.00M0.00M0.01M0.50M1.58M1.61M11.15M17.08M14.74M14.38M19.03M
Revenue & cost
Revenue (Quarter)
0.03M
Operating items
Research & Development (Quarter)
0.15M0.19M9.52M0.36M0.04M3.00M6.59M0.04M1.10M1.95M2.62M2.17M1.06M1.02M1.85M1.40M2.32M1.20M1.67M1.30M
Selling, General & Administrative (Quarter)
2.10M2.62M6.22M3.01M3.15M1.56M2.25M2.24M3.05M2.48M2.26M2.07M2.31M1.59M5.47M1.63M1.81M1.31M1.56M1.42M
Restructuring Costs (Quarter)
0.28M0.38M-0.67M0.70M0.04M0.27M
Other Operating Expenses (Quarter)
1.85M2.66M0.67M14.23M1.62M-0.27M-2.08M1.39M-0.59M9.70M
Operating Expenses (Quarter)
4.38M3.97M15.74M18.31M4.84M4.56M6.75M3.67M4.16M4.43M4.88M4.24M3.37M12.31M7.32M3.04M4.13M2.52M3.24M2.71M
Operating Income (Quarter)
-4.38M-3.97M-15.74M-18.31M-4.84M-4.56M-6.75M-3.67M-4.16M-4.43M-4.88M-4.24M-3.37M-12.31M-7.32M-3.04M-4.13M-2.52M-2.92M-2.69M
EBIT (Quarter)
-4.38M-3.97M-15.74M-18.31M-4.84M-4.56M-6.75M-3.67M-4.16M-4.43M-4.88M-4.24M-3.37M-12.31M-7.32M-3.04M-4.13M-2.52M-2.92M-2.69M
Non-operating items
Non Operating Investment Income (Quarter)
-0.07M-0.14M-0.18M-0.04M-0.03M-0.04M
Interest & Investment Income (Quarter)
0.03M0.01M0.01M0.01M0.00M0.00M0.01M0.00M0.05M0.26M0.22M0.22M0.24M0.19M0.15M0.16M
Other Non Operating Income (Quarter)
-0.99M1.78M-1.86M-0.27M-0.27M-0.47M-14.19M0.10M-0.03M-0.16M0.01M0.08M-0.13M0.12M-0.28M0.14M1.59M-0.42M-0.55M0.00M
Non Operating Income (Quarter)
0.32M1.78M-0.02M3.24M0.39M1.74M0.35M-0.14M0.30M1.81M-0.29M-0.46M-0.06M
Net income details
EBT (Quarter)
-5.37M-1.32M-16.78M-4.31M-5.10M-5.03M-3.14M-3.35M-2.38M-4.45M-1.64M-3.85M-1.63M-11.97M8.92M-2.73M-2.32M-2.81M-3.37M-2.75M
Tax Provisions (Quarter)
0.03M0.04M0.04M-1.23M0.00M0.01M-0.30M-2.48M-0.00M-0.38M
Profit After Tax (Quarter)
-5.40M-1.35M-16.82M-3.08M-5.10M-5.68M-1.57M-3.35M-2.38M-4.54M-1.72M-3.84M-1.63M-11.59M-7.11M-2.73M-2.32M-2.65M-4.04M-2.75M
Income from Non-Controlling Interests (Quarter)
1.06M0.06M0.41M-0.12M0.18M
Income from Continuing Operations (Quarter)
-5.40M-1.35M-16.82M-3.08M-5.10M-5.04M-2.84M-3.35M-2.38M-4.45M0.84M-3.84M-1.63M-11.59M8.92M-2.73M-2.32M-2.81M-3.37M-2.75M
Consolidated Net Income (Quarter)
-5.40M-1.35M-16.82M-3.08M-5.10M-5.04M-2.84M-3.35M-2.38M-4.45M0.84M-3.84M-1.63M-11.59M8.92M-2.73M-2.32M-2.81M-3.37M-2.75M
Income towards Parent Company (Quarter)
-5.40M-1.35M-16.82M-3.08M-5.10M-5.04M-2.84M-3.35M-2.38M-4.45M0.84M-3.84M-1.63M-11.59M8.92M-2.73M-2.32M-2.81M-3.37M-2.75M
Preferred Dividend Payments (Quarter)
1.57M1.38M1.65M0.00M7.29M0.23M0.07M
Net Income towards Common Stockholders (Quarter)
-5.40M-1.35M-16.82M-4.65M-6.48M-6.68M-3.10M-3.36M-9.79M-5.55M-1.72M-3.88M-1.67M-12.15M-7.45M-2.73M-2.32M-2.81M-3.37M-2.75M
Additional items
EPS (Basic) (Quarter)
-0.90M-0.15M-2.10M-0.47M-0.59M-0.56M-0.28M-0.10M-0.02M-0.00M-518.99-664.16-3.34-7.71-4.64-0.25-0.15-0.19-0.23-0.17
EPS (Diluted) (Quarter)
-0.90M-0.15M-2.10M-0.47M-0.59M-0.56M-0.28M-0.10M-0.02M-0.00M-518.99-664.16-3.34-24.34-14.93-5.47-4.65-5.62-6.76-5.52
Shares Outstanding (Quarter)
6.009.008.0010.0011.0012.0011.0032.00621.000.00M0.00M0.01M0.50M1.58M1.61M11.15M15.54M14.74M14.38M15.97M
Shares Outstanding (Diluted) (Quarter)
6.009.008.0010.0011.0012.0011.0032.00621.000.00M0.00M0.01M0.50M0.50M0.50M0.50M0.50M0.50M0.50M0.50M
EBITDA (Quarter)
-4.38M-3.97M-15.74M-18.31M-4.84M-4.56M-6.75M-3.67M-4.16M-4.43M-4.88M-4.24M-3.37M-12.31M-7.32M-3.04M-4.13M-2.52M-2.92M-2.69M
Interest Expenses (Quarter)
2.38M0.03M0.02M0.04M0.79M0.04M0.20M0.09M0.14M0.03M0.23M0.10M0.43M0.05M-0.38M0.06M0.01M0.06M0.07M0.23M
Tax Rate (Quarter)
-0.56-2.66-0.2128.49-0.08-0.109.65151.430.103.15